BR112012021444A2 - polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas. - Google Patents

polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas.

Info

Publication number
BR112012021444A2
BR112012021444A2 BR112012021444A BR112012021444A BR112012021444A2 BR 112012021444 A2 BR112012021444 A2 BR 112012021444A2 BR 112012021444 A BR112012021444 A BR 112012021444A BR 112012021444 A BR112012021444 A BR 112012021444A BR 112012021444 A2 BR112012021444 A2 BR 112012021444A2
Authority
BR
Brazil
Prior art keywords
individual
polymer
bile salts
preparing
pharmaceutical composition
Prior art date
Application number
BR112012021444A
Other languages
English (en)
Inventor
Angela Lee
David Bergbreiter
Deidre Madsen
Elizabeth Goka
Eric Connor
Faleh Salaymeh
Grace Quaker
Hongmin Zhang
Inez Lees
Jordon Kopping
Jun Shao
Kalpesh Biyani
Michael James Cope
Paul Mansky
Scott Hecker
Yongqi Mu
Original Assignee
Relypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Relypsa Inc filed Critical Relypsa Inc
Publication of BR112012021444A2 publication Critical patent/BR112012021444A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
    • C08F20/52—Amides or imides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F22/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides or nitriles thereof
    • C08F22/36—Amides or imides
    • C08F22/38—Amides
    • C08F22/385—Monomers containing two or more (meth)acrylamide groups, e.g. N,N'-methylenebisacrylamide
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/36—Amides or imides
    • C08F222/38—Amides
    • C08F222/385—Monomers containing two or more (meth)acrylamide groups, e.g. N,N'-methylenebisacrylamide
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F232/00—Copolymers of cyclic compounds containing no unsaturated aliphatic radicals in a side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic ring system
    • C08F232/08—Copolymers of cyclic compounds containing no unsaturated aliphatic radicals in a side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic ring system having condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, método para tratar doença, de remoção de sais biliares de um indivíduo animal, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas. a presente invenção fornece polímeros de amina e amida reticulados eficazes para ligar e remover sais biliares do trato gastrointestinal. estes polímeros de ligação a ácido biliar ou composições farmacêuticas dos mesmos podem ser administrados a indivíduos para tratar várias condições, incluindo hipercolesteremia, diabetes, prurido, síndrome do intestino irritável-diarréia (ibs-d), má absorção de ácido biliar e similares.
BR112012021444A 2010-02-24 2011-02-24 polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas. BR112012021444A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30781410P 2010-02-24 2010-02-24
US30781110P 2010-02-24 2010-02-24
PCT/US2011/026099 WO2011106542A2 (en) 2010-02-24 2011-02-24 Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants

Publications (1)

Publication Number Publication Date
BR112012021444A2 true BR112012021444A2 (pt) 2016-05-31

Family

ID=44310840

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012021444A BR112012021444A2 (pt) 2010-02-24 2011-02-24 polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas.

Country Status (9)

Country Link
US (2) US9181364B2 (pt)
EP (2) EP2539380B1 (pt)
JP (3) JP5865847B2 (pt)
CN (2) CN105017481B (pt)
AU (2) AU2011220742B2 (pt)
BR (1) BR112012021444A2 (pt)
CA (1) CA2790999C (pt)
ES (1) ES2549513T3 (pt)
WO (1) WO2011106542A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112011100657T5 (de) 2010-02-24 2013-02-28 Relypsa, Inc. Amin-polymere zur verwendung als gallensäuresequestriermittel
WO2013087237A1 (en) * 2011-12-13 2013-06-20 Synthon Bv Purification of sevelamer and related polyallylamines
KR102081560B1 (ko) * 2012-02-09 2020-02-25 라이프 테크놀로지스 코포레이션 친수성 중합체성 입자 및 그의 제조 방법
PE20151766A1 (es) * 2013-03-15 2015-12-11 Genzyme Corp Agentes quelantes de precursores de producto final de glicacion avanzada (age)
DK3003327T3 (en) 2013-06-05 2017-10-23 Tricida Inc PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION
US10435528B2 (en) 2013-09-17 2019-10-08 Aquanano Llc High-capacity anion exchange materials
CN103585632A (zh) * 2013-11-19 2014-02-19 韩源平 胆汁酸螯合剂或/和维生素d在制备防治非酒精性脂肪性肝病药物中的应用
KR102512890B1 (ko) 2014-06-13 2023-03-21 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐 제제
DK3593808T3 (da) 2014-12-10 2021-02-01 Tricida Inc Proton-bindingspolymerer til oral indgivelse
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
EP3317314B1 (en) 2015-07-02 2020-01-08 Life Technologies Corporation Polymer substrates formed from carboxy functional acrylamide
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
CN106309436A (zh) * 2016-07-25 2017-01-11 宁波大学 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途
JP6792640B2 (ja) 2016-12-28 2020-11-25 富士フイルム株式会社 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法
CN111225674A (zh) 2017-10-16 2020-06-02 富士胶片株式会社 高磷血症治疗剂
AU2018352766B2 (en) 2017-10-16 2021-09-23 Fujifilm Corporation Hyperphosphatemia treatment agent, and particles
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
CN110511322B (zh) * 2019-08-29 2020-10-02 西北大学 一种快速葡萄糖响应的互穿网络聚合物微凝胶及其制备方法
WO2024040380A1 (zh) * 2022-08-22 2024-02-29 中美华世通生物医药科技(武汉)股份有限公司 铵盐聚合物及其制备方法和作为胆汁酸螯合剂的用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
JPH066667A (ja) 1992-06-22 1994-01-14 Canon Inc ぶれ検出装置及びぶれ補正装置
EP0580079B1 (de) * 1992-07-22 1996-12-11 Hoechst Aktiengesellschaft Vernetzte, stickstoffhaltige Vinylcopolymere, Verfahren zu ihrer Herstellung sowie die Verwendung dieser Verbindungen
DE59307535D1 (de) * 1992-07-22 1997-11-20 Hoechst Ag Hydrophile Zentren aufweisende Polyvinylamin-Derivate, Verfahren zu ihrer Herstellung sowie die Verwendung der Verbindungen als Arzneimittel, Wirkstoffträger und Nahrungsmittelhilfsstoff
US5556619A (en) 1992-08-20 1996-09-17 The Du Pont Merck Pharmaceutical Company Crosslinked polymeric ammonium salts
US5900475A (en) 1994-06-10 1999-05-04 Geltex Pharmaceuticals, Inc. Hydrophobic sequestrant for cholesterol depletion
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5414068A (en) 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
AU2446497A (en) 1997-03-25 1998-10-20 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers combined with a calcium supplement for oral administration
US5925379A (en) 1997-03-27 1999-07-20 Geltex Pharmaceuticals, Inc. Interpenetrating polymer networks for sequestration of bile acids
US6290947B1 (en) 1997-09-19 2001-09-18 Geltex Pharmaceuticals, Inc. Ionic polymers as toxin-binding agents
JP3363143B2 (ja) * 1998-10-12 2003-01-08 中外製薬株式会社 リン酸結合性ポリマー粒子
JP4749649B2 (ja) * 1998-10-12 2011-08-17 中外製薬株式会社 リン酸結合性ポリマー
US6482402B1 (en) 1999-05-13 2002-11-19 Geltex Pharmaceuticals, Inc. Antimicrobial compositions and methods
US6180754B1 (en) * 1999-09-03 2001-01-30 The Dow Chemical Company Process for producing cross-linked polyallylamine polymer
US6362266B1 (en) * 1999-09-03 2002-03-26 The Dow Chemical Company Process for reducing cohesiveness of polyallylamine polymer gels during drying
MXPA02002353A (es) 1999-09-08 2002-07-30 Boehringer Ingelheim Pharma Ligandos ajustados electronicamente.
ATE343627T1 (de) * 1999-12-22 2006-11-15 Procter & Gamble Riechstoffkompositionen mit erhöhter viskosität und verfahren zu ihrer herstellung
ES2268013T3 (es) * 2001-04-18 2007-03-16 Genzyme Corporation Formas de polialilamina bajas de sal.
KR20040018359A (ko) 2001-04-18 2004-03-03 젠자임 코포레이션 지방족 폴리아민으로 ｘ 증후군을 치료하는 방법
DE10124387A1 (de) * 2001-05-18 2002-11-28 Basf Ag Hydrophob modifizierte Polyethylenimine und Polyvinylamine zur Antiknitterausrüstung von cellulosehaltigen Textilien
WO2004022524A2 (en) 2002-09-06 2004-03-18 University Of Pittsburgh N-vinylformamide derivatives, polymers formed therefrom and synthesis thereof
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US20050211624A1 (en) * 2004-03-23 2005-09-29 Vane Leland M Hydrophilic cross-linked polymeric membranes and sorbents
US20060177415A1 (en) 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
JP4547620B2 (ja) * 2004-12-02 2010-09-22 日東紡績株式会社 架橋アリルアミン類重合体の製造方法
CA2601236A1 (en) * 2005-03-16 2006-09-21 Usv Limited An improved process for the preparation of crosslinked polyallylamine polymer
JP2009507019A (ja) 2005-09-02 2009-02-19 ジェンザイム・コーポレーション リン酸塩を除去する方法およびそれに使用される重合体
CA2652242C (en) * 2006-05-18 2016-04-26 Hercules Incorporated Michael addition adducts as additives for paper and papermaking
US20090110907A1 (en) * 2007-10-29 2009-04-30 Jiang Dayue D Membranes Based On Poly (Vinyl Alcohol-Co-Vinylamine)
JP2009179724A (ja) * 2008-01-31 2009-08-13 Toray Ind Inc 架橋ポリビニルアミン又はその酸付加塩、及びその医薬用途
DE112011100657T5 (de) 2010-02-24 2013-02-28 Relypsa, Inc. Amin-polymere zur verwendung als gallensäuresequestriermittel
WO2011106545A1 (en) 2010-02-24 2011-09-01 Relypsa, Inc. Polyimidazoles for use as bile acid sequestrants

Also Published As

Publication number Publication date
AU2011220742B2 (en) 2016-02-25
CA2790999A1 (en) 2011-09-01
JP2015038225A (ja) 2015-02-26
EP2539380A2 (en) 2013-01-02
US20130022570A1 (en) 2013-01-24
EP2998329A3 (en) 2016-04-06
AU2016203432B2 (en) 2018-07-26
CN102858817A (zh) 2013-01-02
WO2011106542A2 (en) 2011-09-01
JP2013520561A (ja) 2013-06-06
WO2011106542A3 (en) 2011-11-10
JP6247740B2 (ja) 2017-12-13
ES2549513T3 (es) 2015-10-28
JP2017048398A (ja) 2017-03-09
US9181364B2 (en) 2015-11-10
JP5865847B2 (ja) 2016-02-17
CN102858817B (zh) 2015-09-02
EP2539380B1 (en) 2015-08-19
CN105017481B (zh) 2018-10-02
US20160051576A1 (en) 2016-02-25
CA2790999C (en) 2019-05-14
CN105017481A (zh) 2015-11-04
AU2016203432A1 (en) 2016-06-16
US10272103B2 (en) 2019-04-30
AU2011220742A1 (en) 2012-09-13
EP2998329A2 (en) 2016-03-23

Similar Documents

Publication Publication Date Title
BR112012021444A2 (pt) polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas.
BR112012021448A2 (pt) polímero de amina, método para tratar doença, método de remoção de sais biliares de um indivíduo animal, método para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina.
BR112012021446A2 (pt) polímero de amina, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, método para tratar doença, métodos de remoção de sais biliares de um indivíduo animal, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina.
BRPI0810246A2 (pt) Inibidores da dpp-iv incluindo o grupo beta-amino, método de preparação do mesmo e composição farmacêutica contendo o mesmo para prevenção e tratamento da diabetes ou obesidade.
CY1119010T1 (el) Συνθεση και μεθοδος για τη θεραπευτικη αγωγη του διαβητη
WO2013058833A8 (en) Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2012106363A3 (en) Treatment of tauopathies
BR112013032667A2 (pt) polipeptídeo de ligação a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o polipeptídeo, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito, método de tratamento de disfunção relacionada ao colesterol em um sujeito, método de tratamento de hipercolesterolemia em um sujeito, método de inibição da ligação de pcsk9 a ldlr e método de detecção da proteína pcsk9 em uma amostra
BRPI0813499B8 (pt) compostos pirimidina carboxamidas úteis como inibidores da quinase raf, composição farmacêutica compreendendo os mesmos e método de preparação dos mesmos
EA201490852A1 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
EA200602210A1 (ru) Связывающие молекулы, способные нейтрализовать вирус бешенства, и их применение
EA029939B8 (ru) Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение
BR112013011685A2 (pt) composição farmaceuticamente aceitável, formulação farmaceuticamente aceitável, emplastro transdérmico, método de tratamento de um distúrbio neurológico ou motora, composição líquida farmaceuticamente aceitável, e processo
NO20091321L (no) Menneskelige bindingsmolekyler i stand til a noytralisere influensavirus H5N1 og anvendelser derav
BR112012021652A2 (pt) composto, uso do mesmo, e, composição farmacêutica
BRPI0921687A2 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
BR112013028779B8 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
WO2012007880A3 (en) Modified single domain antigen binding molecules and uses thereof
EA201001749A1 (ru) Способ лечения недифференцированного артрита
BR112015007818A2 (pt) composto, composição farmacêutica, e, uso de um composto e de uma composição farmacêutica
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
NO20076605L (no) Coalescing apparatus, emulsion treatment system and method for coalescing
BR112012021656A2 (pt) composto, uso do mesmo, e, composição farmacêutica
EA201290158A1 (ru) Композиция и способ лечения диабета

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DAANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012,ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C08F 20/52 , C08F 22/38 , C08L 39/02 , C08F 26/02 , C08F 32/08

Ipc: A61K 31/785 (2006.01), C08F 22/38 (2006.01), C08L

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements